Concepedia

Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)

Hywel Cooper, Eugene Healy, Jeffrey Theaker, PS Friedmann

Clinical and Experimental Dermatology · 2003 · 73 citations · 9 references

DOI

Concepts

Abstract

We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.

References

9

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text

, , +14

Humoral Immunity Due to Long-Lived Plasma Cells

Mark K. Slifka, Rustom Antia, Jason K. Whitmire et al. · Immunity · 1998 · 1.3K citations · Full text

, , +14

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

DG Maloney, TM Liles, DK Czerwinski et al. · Blood · 1994 · 753 citations

, , +17

Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity.

Kailash C. Bhol, Kannan Natarajan, Neville Nagarwalla et al. · Proceedings of the National Academy of Sciences · 1995 · 202 citations

, , +17

Detection of Antigen-Specific B Cells in Patients with Pemphigus Vulgaris by Enzyme-Linked Immunospot Assay: Requirement of T Cell Collaboration for Autoantibody Production

Koji Nishifuji, Masayuki Amagai, Masataka Kuwana et al. · Journal of Investigative Dermatology · 2000 · 134 citations · Full text

, , +17